Shopping Cart
  • Remove All
  • TargetMol
    Your shopping cart is currently empty

Inhibitory Antibodies

A monoclonal antibody is secreted by a single B lymphocyte clone which can only produce a kind of proprietary antibody against an antigen-determining cluster, and has the characteristics of single biological activity and particular specificity of binding with antigen. The active sites of monoclonal antibody drugs involve a variety of tumor-related signaling pathways and targets. For example, the most common targets are epidermal growth factor receptor (EGFR), vascular endothelial growth factor (VEGF), and epidermal growth factor receptor -2 (her-2 /neu, or egfr-2). Besides, there is a group of targets that are getting a lot of attention called “immune checkpoints”. After the activation of immune cells that regulate the anti-tumor immune response, a variety of highly expressed receptors on the surface of immune cells bind to the highly expressed ligands on the surface of tumor cells to reduce the strength of the immune response, thus down-regulating the intensity of tumor-related immune response. These immunoregulatory sites are known as immune checkpoints. Currently, the most widely studied immune checkpoints are PD-1, PD-L1, and CTLA-4. Targetmol provides xnum monoclonal antibody drugs, including the above immune checkpoint inhibitors and other types of targeted antibody inhibitors, for scientific research only.

FilterHomeInhibitory Antibodies
TargetMol
Anti-Mouse PD-1 Antibody (RMP1-14)
T78269
RMP1-14 is an IgG1-like immunoglobulin and anti-Mouse PD-1 antibody that blocks PD-1 PD-L1 signaling.
  • $99
Backorder
Size
QTY
TargetMol | Inhibitor Hot
Trastuzumab
T9912180288-69-1
Trastuzumab is a humanized monoclonal antibody for patients with invasive breast cancers that overexpress HER2. Trastuzumab has been clinically used to treat HER2 Positive Metastatic Breast Cancer and HER2 Positive Gastric Cancer.
  • $157
In Stock
Size
QTY
TargetMol | Inhibitor Hot
Cetuximab
T9905205923-56-4
Cetuximab (C225) is a monoclonal antibody that is an inhibitor of human epidermal growth factor receptor (EGFR) (Kd=0.201 nM). Cetuximab has antitumor activity, inhibiting tumor cell proliferation and inducing apoptosis.
  • $197
In Stock
Size
QTY
TargetMol | Inhibitor Hot
TargetMol | Citations Cited
Pembrolizumab
T99081374853-91-4
Pembrolizumab (MK-3475) is a humanized monoclonal antibody inhibiting the PD-1 receptor and the first in the class of agents called the HER2 dimerization inhibitors that impairs the ability of HER2 to bind to other members of the HER family.
  • $218
In Stock
Size
QTY
TargetMol | Inhibitor Hot
Trastuzumab deruxtecan
T366461826843-81-5
Trastuzumab deruxtecan (T-DXd) is an antibody-active molecule conjugate (ADC) with anticancer and antitumor activity, which is composed of a monoclonal antibody targeting human epidermal growth factor receptor 2 (HER2) coupled to a topoisomerase I inhibitor (DXd). Trastuzumab deruxtecan has an improved effect on the treatment of HER2-positive breast cancer and gastric cancer.
  • $728
In Stock
Size
QTY
TargetMol | Inhibitor Hot
Atezolizumab
T99021380723-44-3
Atezolizumab is an antibody inhibitor, a humanized monoclonal antibody, IgG1, which targets PD-L1 and blocks the interaction of PD-L1 with PD-1. Atezolizumab has antitumor activity and promotes T-cells to attack tumor cells.
  • $229
In Stock
Size
QTY
TargetMol | Inhibitor Hot
Evolocumab
T99201256937-27-5
Evolocumab is an inhibitor of the humanized monoclonal antibody PCSK9. It binds to circulating PCSK9 protein, resulting in inhibition of PCSK9 binding to LDLR. It can be used in studies of hypercholesterolemia and atherosclerotic cardiovascular disease.
  • $397
In Stock
Size
QTY
TargetMol | Inhibitor Hot
Rituximab
T9910174722-31-7
Rituximab is an anti-CD20 chimeric monoclonal antibody used to study certain autoimmune diseases and cancers.
  • $229
In Stock
Size
QTY
TargetMol | Inhibitor Hot
TargetMol | Citations Cited
Bevacizumab
T9904216974-75-3
Bevacizumab, a humanized monoclonal antibody, specifically and with high affinity binds to all isoforms of VEGF-A.
  • $129
In Stock
Size
QTY
TargetMol | Inhibitor Hot
TargetMol | Citations Cited
Infliximab
T9921170277-31-3
Infliximab is a monoclonal antibody, a human-mouse chimeric monoclonal antibody that inhibits TNF-α and prevents TNF-α from interacting with TNFR1 and TNFR2. Infliximab can be used to treat Crohn's disease and rheumatoid arthritis.
  • $98
In Stock
Size
QTY
TargetMol | Inhibitor Hot
TargetMol | Citations Cited
Dupilumab
T136661190264-60-8
Dupilumab (REGN-668) is a fully human monoclonal antibody targeting the alpha subunit of the interleukin-4 receptor, thereby inhibiting IL-4 and IL-13 signaling. As a systemic immunomodulator, it has demonstrated efficacy in improving atopic dermatitis.
  • $239
In Stock
Size
QTY
TargetMol | Inhibitor Hot
Adalimumab
T9901331731-18-1
Adalimumab (anti-TNF-alpha) is the first fully human recombinant IgG1 monoclonal antibody that specifically targets human TNF-alpha.
  • $213
In Stock
Size
QTY
TargetMol | Inhibitor Hot
TargetMol | Citations Cited
Nivolumab
T9907946414-94-4
Nivolumab is a monoclonal antibody, a humanized IgG4 antibody to PD-1. Nivolumab has antitumor activity and is used in the treatment of melanoma, non-small cell lung cancer, renal cell carcinoma and others.
  • $182
In Stock
Size
QTY
TargetMol | Inhibitor Hot
Disitamab vedotin
T395952136633-23-1
Disitamab vedotin (RC-48) is a newly developed antibody-active molecule conjugate (ADC) targeting human epidermal growth factor receptor 2 (HER2), consisting of hertuzumab coupled to monomethyl auristatin E (MMAE) via a cleavable linker. Disitamab vedotin showed anti-tumor and anti-proliferative activities in gastric cancer cells with different HER-2 expression levels and inhibited the expression of HER-2 protein in gastric cancer cells.
  • $347
In Stock
Size
QTY
TargetMol | Inhibitor Hot
Ipilimumab
T9906477202-00-9
Ipilimumab (anti-CTLA-4) is an immunomodulatory monoclonal antibody directed against the cell surface antigen CTLA-4 and also a type of immune checkpoint inhibitor.
  • $456
In Stock
Size
QTY
TargetMol | Inhibitor Hot
TargetMol | Citations Cited
Datopotamab deruxtecan
T397302238831-60-0
Datopotamab deruxtecan (DS-1062) is a trophoblast cell surface antigen 2 (TROP2)-targeted antibody-drug conjugate (ADC) with antitumor activity. Datopotamab deruxtecan induces significant antibody-dependent cellular cytotoxicity in the presence of peripheral blood lymphocytes and inhibits tumor growth in xenograft models.
  • $1,060
In Stock
Size
QTY
TargetMol | Inhibitor Hot
Etanercept
T37445185243-69-0
Etanercept is a fusion protein consisting of the soluble portion of the p75-tumor necrosis factor receptor (TNFR) and the Fc fragment of human IgG1 and is commonly used to treat patients with rheumatoid arthritis.[1]
  • $328
In Stock
Size
QTY
TargetMol | Inhibitor Hot
TargetMol | Citations Cited
Sacituzumab
T353971796566-95-4
Sacituzumab is a humanized IgG1 monoclonal antibody utilized in the synthesis of antibody-active small-molecule couplings (naked antibody to Sacituzumab govitecan). It exhibits potential antitumor activity and is employed in tumor research.
  • $163
In Stock
Size
QTY
TargetMol | Inhibitor Hot
Datopotamab
T9901A-0072267989-53-5
Datopotamab (CDP7657) is a TROP2-targeting antibody that is a naked antibody to Datopotamab deruxtecan and can be used to synthesize active antibody conjugators (Datopotamab deruxtecan).
  • $255
In Stock
Size
QTY
Natalizumab
T12177189261-10-7
Natalizumab used for the treatment of relapsing remitting multiple sclerosis and Crohn's disease.
  • $169
In Stock
Size
QTY
TargetMol | Inhibitor Hot
Avelumab
T99031537032-82-8
Avelumab, a fully human IgG1 anti-PD-L1 monoclonal antibody, exhibits potential antibody-dependent cell-mediated cytotoxicity.
  • $289
In Stock
Size
QTY
Ponsegromab
T767742368950-15-4
Ponsegromab (PF 06946860) is a selective and effective humanized anti-GDF15 antibody inhibitor with anti-cachexic activity. It binds to GDF15, preventing its interaction with GFRAL and disrupting GDF15 GFRAL mediated signaling. Ponsegromab has potential anticancer activity and can be used to treat cancer patients with cancer anorexia cachexia syndrome.
  • $297
In Stock
Size
QTY
Alirocumab
T99161245916-14-6
Alirocumab is a human monoclonal antibody that inhibits PCSK9. It is produced by recombinant DNA technology in Chinese hamster ovary cell suspension culture.
  • $372
In Stock
Size
QTY
Secukinumab
T99301229022-83-6
Secukinumab is a fully humanized monoclonal anti-IL-17A antibody and the first in its class to be approved by the US Food and Drug Administration for the treatment of moderate to severe plaque psoriasis.
  • $147
In Stock
Size
QTY
Ustekinumab
T9913815610-63-0
Ustekinumab is an anti-IL-12 IL-23 IgG1κ human monoclonal antibody.
  • $455
In Stock
Size
QTY
Tocilizumab
T9911375823-41-9
Tocilizumab (Anti-Human IL6R) is a neutralizing antibody against human interleukin-6 receptor (IL-6R) that blocks the binding of IL-6 to IL-6R, thereby inhibiting both classical and trans signaling. It can be used to study rheumatoid arthritis and has been suggested as a possible drug for the treatment of severe COVID-19.
  • $223
In Stock
Size
QTY
TargetMol | Inhibitor Hot
TargetMol | Citations Cited
Carotuximab
T769411268714-50-6
Carotuximab (DE-122) is a novel endocholine antibody with strong antiangiogenic and anti-inflammatory activity. Carotuximab blocks endothelial glycoprotein (CD105) and its downstream Smad signaling pathway. Carotuximab has immunomodulatory and antitumor effects to prevent human endothelial dysfunction induced by hypercholesterolemia and hyperglycemia.
  • $247
In Stock
Size
QTY
Relatlimab
T9901A-0011673516-98-7
Relatlimab(BMS-986016) is a monoclonal antibody targeting human anti-LAG-3, generated by immunization of transgenic mice with human immunoglobulin carrying recombinant LAG-3 protein.Relatlimab has a blocking effect, blocking the interaction of LAG-3 MHC II (IC50: 0.67 nM) and LAG-3 FGL1 (IC50: 0.019 nM). Relatlimab is often used with Nivoluma to treat advanced melanoma.
  • $166
In Stock
Size
QTY
Narsoplimab
T768702108782-45-0
Narsoplimab (OMS 721) is a selective whole-human immunoglobulin gamma-4 (IgG4) monoclonal antibody and a mannan-binding lectin-associated serine protease-2 (MASP-2) inhibitor that binds MASP-2 to prevent lectin pathway activation and inhibit the agglutinin pathway. It is used to study diseases associated with hematopoietic stem cell transplantation in adults.
  • $347
In Stock
Size
QTY
Panitumumab
T9927339177-26-3
Panitumumab is a fully human IgG2 monoclonal antibody targeting the epidermal growth factor receptor EGFR).
  • $178
In Stock
Size
QTY
Zolbetuximab
T9901A-0051496553-00-4
Zolbetuximab(IMAB362) is a monoclonal antibody that specifically targets Claudin-18.2.Zolbetuximab has potential antitumor activity, mediating killing of Claudin-18.2-positive cells through an immune effector mechanism.Zolbetuximab is used in the study of gastrointestinal adenocarcinomas and pancreatic tumors.
  • $263
In Stock
Size
QTY
Camrelizumab
T375351798286-48-2
Camrelizumab (SHR-1210) is a human IgG4-κ monoclonal antibody with high affinity directed against PD-1, binding PD-1 with an affinity of up to 3 nM and inhibiting PD-1 PD-L1 with an IC50 of 0.70 nM. Camrelizumab exhibits anti-tumor activity and is well tolerated in cancers, including NSC-LC, ESCC, Hodgkin's lymphoma, and advanced HCC.
  • $163
Backorder
Size
QTY
Emapalumab
T767421709815-23-5
Emapalumab (NI-0501) is an IgG1 monoclonal antibody that humanizes human monoclonal antibodies against interferon gamma, blocking its binding to cell surface receptors and activating inflammatory signaling. Emapalumab has a high binding force (Kd=1.4 pM) to free IFN-γ and to IFN-γ bound to its receptor. Emapalumab can be used in the study of hemophagocytic lymphohistiocytosis (HLH).
  • $238
In Stock
Size
QTY
Human IgG1 kappa, Isotype Control
T78242
Human IgG1 kappa, Isotype Control is a humanized IgG-like monoclonal antibody and an isotype control antibody for human IgG1κ.
  • $247
In Stock
Size
QTY
Monalizumab
T766911228763-95-8
Monalizumab is a novel immune checkpoint inhibitor targeting natural killer cell population 2A (NKG2A). Monalizumab is a humanized monoclonal antibody against NKG2A that induces IFN-γ production, thereby activating natural killer cell function. Monalizumab has antitumor activity and can be used to study neck squamous cell carcinoma (HNSCC).
  • $438
In Stock
Size
QTY
Pertuzumab
T9909380610-27-5
Pertuzumab (anti-HER2) a humanized monoclonal antibody and the first in the class of agents called the HER2 dimerization inhibitors impairs the ability of HER2 to bind to other members of the HER family.
  • $189
In Stock
Size
QTY
Pamrevlumab
T76804946415-13-0
Pamrevlumab (FG-3019) is a human antibody with affinity for connective tissue growth factor (CTGF) and is involved in anti-CTGF therapy for the treatment of idiopathic pulmonary fibrosis (IPF).
  • $139
In Stock
Size
QTY
Mosunetuzumab
T766921905409-39-3
Mosunetuzumab (BCT-4465A) is a humanized antibody based on immunoglobulin G1 that targets CD20 (B cells) and CD3 (T cells). Mosunetuzumab redirects T cells to engage and eliminate malignant B cells and can be used to study relapsed or refractory (R R) B-cell non-Hodgkin lymphoma (B-NHL) and refractory follicular lymphoma.
  • $228
In Stock
Size
QTY
Rosmantuzumab
T777501684393-04-1
Rosmantuzumab (OMP-131R10) is a humanized monoclonal antibody against R-spondin 3 (RSPO3). Rosmantuzumab has potential antitumor activity and can be used to study advanced relapsed refractory solid tumors.
  • $228
In Stock
Size
QTY
Guselkumab
T383621350289-85-8
Guselkumab (CNTO 1959) is a recombinant human IgG1 monoclonal antibody targeting the IL-23p19 subunit. Guselkumab binds to human cynomolgus monkey IL-23 with Kd values of 3.3 and 1.9 pmol L, respectively. Guselkumab can inhibit the production of cytokines downstream of IL-23 signaling pathway, and can be used in the study of psoriatic arthritis.
  • $663
In Stock
Size
QTY
Pepinemab
T773922097151-87-4
Pepinemab(VX 15 2503) is a humanized IgG4 monoclonal antibody targeting sematone 4D. Pepinemab has anti-cancer activity and blocks the activity of SEMA4D, which is used to study degenerative diseases similar to Alzheimer's disease.
  • $198
In Stock
Size
QTY
Cergutuzumab amunaleukin
T769441509916-03-3
Cergutuzumab amunaleukin (CEA-IL2v) is a CEA-targeted IL-2 variant immunocytokine for combination cancer immunotherapy with immunostimulatory and anti-tumor activities for the study of solid cancers.
  • $428
In Stock
Size
QTY
Alemtuzumab
T9919216503-57-0
Alemtuzumab is a humanized monoclonal antibody against CD52 an antigen found on the surface of normal and malignant lymphocytes.
  • $312
In Stock
Size
QTY
Anetumab
T768571954758-84-9
Anetumab is a novel fully human anti-mesothelin IgG1 antibody that is a naked antibody to Anetumab ravtansine.Anetumab can be used to synthesize the antibody-activated molecule coupling, Anetumab ravtansine.Anetumab can be used to study the treatment of metastatic pleural mesothelioma.
  • $290
In Stock
Size
QTY
Galiximab
T76809357613-77-5
Galiximab (IDEC 114) is a primate-type anti-CD80 immunoglobulin G1 (IgG1)-like monoclonal antibody with antitumor activity that induces in vivo growth inhibition and prolongs survival of B-NHL tumor xenografts. Galiximab has been used in the study of hematologic malignancies.
  • $247
In Stock
Size
QTY
Ozoralizumab
T771261167985-17-2
Ozoralizumab (ATN-103) is a humanized anti-TNFα antibody and a novel TNFα inhibitor.Ozoralizumab binds human serum albumin and can be used to study rheumatoid arthritis.
  • $328
In Stock
Size
QTY
Bavituximab
T77401648904-28-3
Bavituximab (Anti-Human Phosphatidylserine Recombinant Antibody) is a monoclonal antibody targeting phosphatidylserine (PS) with vascular targeting and immunomodulatory properties, capable of reactivating anti-tumor immunity to inhibit tumor growth. It has anti-cancer activity and is frequently used with Paclitaxel and Carboplatin in non-small cell lung cancer studies.
  • $497
In Stock
Size
QTY
Tinurilimab
T774712226224-30-0
Tinurilimab (Bay 1834942) is a monoclonal antibody that targets and inhibits CEACAM6, an immune checkpoint regulator. Tinurilimab can be used in studies about effector T-cells against tumors.
  • $195
In Stock
Size
QTY